

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd. *

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

**ELECTION OF THE MEMBERS OF THE BOARD AND THE BOARD OF SUPERVISORS
APPOINTMENT OF CHAIRMAN, VICE CHAIRMAN AND CHIEF SUPERVISOR
APPOINTMENT OF THE MEMBERS OF THE STRATEGY COMMITTEE,
NOMINATION COMMITTEE, AUDIT COMMITTEE AND REMUNERATION AND ASSESSMENT COMMITTEE
APPOINTMENT OF PRESIDENT, EXECUTIVE PRESIDENT AND VICE PRESIDENTS
AND
CHANGE OF AUTHORISED REPRESENTATIVE**

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Pharmaceuticals Holding Co., Ltd. (the “**Company**”) hereby announces:

ELECTION OF EXECUTIVE DIRECTORS, NON-EXECUTIVE DIRECTORS, INDEPENDENT NON-EXECUTIVE DIRECTORS AND SUPERVISORS

At the annual general meeting of the Company held on 29 June 2023, Mr. SHEN Bo, Mr. LI Yongzhong and Mr. DONG Ming were duly elected by the shareholders of the Company as executive Directors of the eighth session of the Board, Mr. ZHOU Jun, Mr. YAO Jiayong and Mr. CHEN Fashu were duly elected by the shareholders of the Company as non-executive Directors of the eighth session of the Board, Mr. GU Zhaoyang, Mr. Manson FOK and Mr. WANG Zhong were duly elected by the shareholders of the Company as independent non-executive Directors of the eighth session of the Board, and Mr. XU Youli and Mr. MA Jia were duly elected by the shareholders of the Company as supervisors (the “**Supervisors**”) of the eighth session of the board of supervisors of the Company (the “**Board of Supervisors**”), all with effect from 29 June 2023.

Reference is made to the announcement of the Company dated 21 June 2023, in relation to the election of employee representative Supervisor. Mr. YU Weidong was duly elected as an employee

representative Supervisor of the eighth session of the Board of Supervisors by the employees' representatives conference of the Company, with his term revised to take effect from 29 June 2023.

CEASING TO ACT AS DIRECTORS AND SUPERVISORS

Each of Mr. GE Dawei, Mr. CHO Man, Ms. LI An, Mr. CAI Jiangnan and Mr. HONG Liang ceased to act as a Director, Mr. HUAN Jianchun ceased to act as an employee representative Supervisor and Mr. XIN Keng ceased to act as a Supervisor due to the expiry of each of their terms of office as a Director or Supervisor, with effect from 29 June 2023. The Company expressed thanks to the above-mentioned persons for their contributions to the Company during their terms as a Director or Supervisor. Each of the above-mentioned persons has confirmed that he or she has no disagreement with the Board and the Board of Supervisors and there is no matter relating to his or her cessation to act as a Director or Supervisor that need to be brought to the attention of the shareholders of the Company.

APPOINTMENT TO THE BOARD, THE BOARD OF SUPERVISORS, THE BOARD COMMITTEES AND MANAGEMENT

1. Mr. ZHOU Jun, a non-executive Director, has been elected by the Board as the chairman of the eighth session of the Board for a term of three years and Mr. YAO Jiayong, a non-executive Director, has been elected by the Board as the vice chairman of the eighth session of the Board for a term for three years, both with effect from 29 June 2023;
2. Mr. XU Youli, a Supervisor, has been elected by the Board of Supervisors as the chief Supervisor of the eighth session of the Board of Supervisors for a term of three years, with effect from 29 June 2023;
3. Mr. ZHOU Jun, a non-executive Director, has been elected by the Board as the convener of the Strategy Committee of the Board; Mr. CHEN Fashu, a non-executive Director, and Mr. WANG Zhong, an independent non-executive Director, have been elected by the Board as members of the Strategy Committee of the Board;
4. Mr. Manson FOK, an independent non-executive Director, has been elected by the Board as the convener of the Nomination Committee of the Board; Mr. SHEN Bo, an executive Director, and Mr. GU Zhaoyang, an independent non-executive Director, have been elected by the Board as members of the Nomination Committee of the Board;
5. Mr. GU Zhaoyang, an independent non-executive Director, has been elected by the Board as the convener of the Audit Committee of the Board; Mr. Manson FOK, an independent non-executive Director, and Mr. WANG Zhong, an independent non-executive Director, have been elected by the Board as members of the Audit Committee of the Board;
6. Mr. WANG Zhong, an independent non-executive Director, has been elected by the Board as the convener of the Remuneration and Assessment Committee of the Board; Mr. YAO Jiayong, a

non-executive Director, and Mr. GU Zhaoyang, an independent non-executive Director, have been elected by the Board as members of the Remuneration and Assessment Committee of the Board;

7. Mr. SHEN Bo, an executive Director, has been appointed as the president of the Company by the Board, and Mr. LI Yongzhong, an executive Director, has been appointed as the executive president of the Company by the Board for a term until the expiration of the eighth session of the Board, with effect from 29 June 2023; and

8. Mr. ZHAO Yong, Mr. MAO Jianyi, Mr. ZHANG Yaohua, Mr. ZHONG Tao, Mr. PAN Deqing, Mr. LI Dongming and Ms. SHAO Shuai have been appointed by the Board as the vice presidents of the Company; Mr. SHEN Bo has been appointed by the Board to temporarily act as the chief financial officer of the Company; and Mr. ZHONG Tao has been appointed by the Board as the Board secretary and a joint company secretary of the Company, all for a term until the expiration of the eighth session of the Board, with effect from 29 June 2023.

The updated biographical details of Mr. YAO Jiayong, Mr. DONG Ming and Mr. MA Jia are as follows:

Mr. YAO Jiayong was born in May 1966. He graduated from the Second Military Medical University with a bachelor's degree in pharmacy, and obtained a master's degree in military science from the National Defense University with major in the military political work. He is currently serving as deputy secretary of the Party Committee and supervisor of Shanghai Shangshi (Group) Co., Ltd., secretary of the Party Committee of Shanghai Pharmaceutical (Group) Co., Ltd., and secretary of the Party Committee of the Company. He served as political commissar of the Naval Medical Department of the Second Military Medical University, secretary-general of the Shanghai Financial Services Office, deputy secretary of the Party Committee for Financial Affairs in Shanghai, and secretary of the discipline inspection commission and inspector of Shanghai Shangshi (Group) Co., Ltd., etc.

Mr. DONG Ming was born in October 1976. He has obtained a bachelor's degree. He is currently the director (performing the duties of chairman), the chief executive officer (the president) and the legal representative of Yunnan Baiyao Group Co., Ltd. (a company listed on the Shenzhen Stock Exchange with stock code 000538). He successively served as a technical engineer, the director of the fixed network marketing department of the Xi'an representative office, the director of the fixed network products marketing department of the Eastern Europe region, the vice president of Commonwealth of Independent States region, the director of the VIP systems department, the general manager of the Beijing branch, the director of the mobile system department of Huawei Technologies Co., Ltd., and the vice president of China region in Huawei Technologies Co., Ltd..

Mr. MA Jia was born in March 1977 and has obtained a master's degree and is a member of the Chinese Communist Party. Since June 2022, he has been serving as the chief financial officer of Yunnan Baiyao Group Co., Ltd. (a company listed on the Shenzhen Stock Exchange with stock code 000538). Since June 2023, he has concurrently served as the executive director of Yunnan Baiyao Group (Hainan) Co., Ltd.. He successively served as the head of financial management department of Beijing Panasonic

Lighting Source Co., Ltd., a chief financial officer of the subsidiary of the Commonwealth of Independent States region of Huawei Technologies Co., Ltd., manager of IFS changing project (China region), a chief financial officer of Shandong representative office, a chief financial officer of BG Group Operator of China region, China regional chief financial officer/China regional administrative team member from March 2018 to May 2022, responsible for ICT operation and management, risk control, sales and finance, tax, subsidiaries, and other financial business and economic organization construction of China region (excluding Hong Kong, Macao and Taiwan).

Details of the biographies of the other Directors and Supervisors were set out in the Company's supplemental circular of the annual general meeting dated 14 June 2023 and the Company's 2022 Annual Report. As at the date of this announcement, there has been no material change to such information.

CHANGE OF AUTHORISED REPRESENTATIVE

The Board is pleased to announce that, Mr. SHEN Bo has been appointed as the authorised representative (the "**Authorised Representative**") of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, with effect from 29 June 2023. On the same date, Mr. CHO Man ceased to act as the Authorised Representative. Mr. ZHONG Tao will continue to be the other Authorised Representative.

Details of the biography of Mr. SHEN Bo were set out in the Company's 2022 Annual Report. As at the date of this announcement, there has been no change to such information.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd. *
ZHOU Jun
Chairman

Shanghai, the PRC, 30 June 2023

As at the date of this announcement, the executive Directors are Mr. SHEN Bo, Mr. LI Yongzhong and Mr. DONG Ming; the non-executive Directors are Mr. ZHOU Jun, Mr. YAO Jiayong and Mr. CHEN Fashu; and the independent non-executive Directors are Mr. GU Zhaoyang, Mr. Manson FOK and Mr. WANG Zhong.

** For identification purpose only*